Entering the radiopharmaceutical space, Sanofi has signed a licensing agreement with RadioMedix and Orano Med for the development of next generation radioligand medicines for rare cancers. Through the deal, which is worth up to €320 M (US$352.94 M), Sanofi will gain access to the late-stage programme, AlphaMedixTM (212Pb-dotamtate) for the treatment of adult patients with unresectable or metastatic, progressive somatostatin-receptor expressing neuroendocrine tumours. In recent months, radioligand therapies have piqued the interest of several big pharma companies, with high-valued deals being announced by key players such as Bristol Myers Squibb, AstraZeneca, Novartis and Eli Lilly.